FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121781539> ?p ?o ?g. }

• W3121781539 endingPage "337.e1" @default.
• W3121781539 startingPage "328" @default.
• W3121781539 abstract "Background Acute myeloid leukemia (AML) accounts for approximately 20% of pediatric leukemia cases; 30% of these patients experience relapse. The antileukemia properties of natural killer (NK) cells and their safety profile have been reported in AML therapy. We proposed a phase 2, open, prospective, multicenter, nonrandomized clinical trial for the adoptive infusion of haploidentical K562-mb15-41BBL–activated and expanded NK (NKAE) cells as a consolidation strategy for children with favorable and intermediate risk AML in first complete remission after chemotherapy (NCT02763475). Patients and Methods Before the NKAE cell infusion, patients underwent a lymphodepleting regimen. After the NKAE cell infusion, patients were administered low doses (1 × 106/IU/m2) of subcutaneous interleukin-2. The primary study endpoint was AML relapse-free survival. We needed to include 35 patients to demonstrate a 50% reduction in relapses. Results Seven patients (median age, 7.4 years; range, 0.78-15.98 years) were administered 13 infusions of NKAE cells, with a median of 36.44 × 106 cells/kg (range, 6.92 × 106 to 193.2 × 106 cells/kg). We observed chimerism in 4 patients (median chimerism, 0.065%; range, 0.05-0.27%). After a median follow-up of 33 months, the disease of 6 patients (85.7%) remained in complete remission. The 3-year overall survival was 83.3% (95% confidence interval, 68.1-98.5), and the cumulative 3-year relapse rate was 28.6% (95% confidence interval, 11.5-45.7). The study was terminated early because of low patient recruitment. Conclusion This study emphasizes the difficulties in recruiting patients for cell therapy trials, though NKAE cell infusion is safe and feasible. However, we cannot draw any conclusions regarding efficacy because of the small number of included patients and insufficient biological markers." @default.
• W3121781539 created "2021-02-01" @default.
• W3121781539 creator A5000200633 @default.
• W3121781539 creator A5003525440 @default.
• W3121781539 creator A5009172669 @default.
• W3121781539 creator A5010182646 @default.
• W3121781539 creator A5010790189 @default.
• W3121781539 creator A5016641243 @default.
• W3121781539 creator A5018899927 @default.
• W3121781539 creator A5028565626 @default.
• W3121781539 creator A5028970724 @default.
• W3121781539 creator A5030407146 @default.
• W3121781539 creator A5034182883 @default.
• W3121781539 creator A5035825967 @default.
• W3121781539 creator A5038473767 @default.
• W3121781539 creator A5040835120 @default.
• W3121781539 creator A5042926098 @default.
• W3121781539 creator A5043047671 @default.
• W3121781539 creator A5043068650 @default.
• W3121781539 creator A5058462170 @default.
• W3121781539 creator A5061562953 @default.
• W3121781539 creator A5065195484 @default.
• W3121781539 creator A5073130528 @default.
• W3121781539 creator A5076439116 @default.
• W3121781539 creator A5078574933 @default.
• W3121781539 creator A5082194202 @default.
• W3121781539 creator A5083610318 @default.
• W3121781539 creator A5090702243 @default.
• W3121781539 date "2021-05-01" @default.
• W3121781539 modified "2023-10-18" @default.
• W3121781539 title "Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia" @default.
• W3121781539 cites W1608314891 @default.
• W3121781539 cites W1916138910 @default.
• W3121781539 cites W1951555862 @default.
• W3121781539 cites W1964807436 @default.
• W3121781539 cites W1979544480 @default.
• W3121781539 cites W2008770122 @default.
• W3121781539 cites W2018968534 @default.
• W3121781539 cites W2021663709 @default.
• W3121781539 cites W2038408021 @default.
• W3121781539 cites W2048452843 @default.
• W3121781539 cites W2075049419 @default.
• W3121781539 cites W2090858884 @default.
• W3121781539 cites W2103441770 @default.
• W3121781539 cites W2106578986 @default.
• W3121781539 cites W2147068163 @default.
• W3121781539 cites W2165635676 @default.
• W3121781539 cites W2168133698 @default.
• W3121781539 cites W2172763662 @default.
• W3121781539 cites W2253944138 @default.
• W3121781539 cites W2260702256 @default.
• W3121781539 cites W2338392504 @default.
• W3121781539 cites W2403301106 @default.
• W3121781539 cites W2559537906 @default.
• W3121781539 cites W2744856411 @default.
• W3121781539 cites W2773514102 @default.
• W3121781539 cites W2789253330 @default.
• W3121781539 cites W2791643627 @default.
• W3121781539 cites W2795056814 @default.
• W3121781539 cites W2808851949 @default.
• W3121781539 cites W2903041954 @default.
• W3121781539 cites W2925256229 @default.
• W3121781539 cites W2942184366 @default.
• W3121781539 cites W2950402676 @default.
• W3121781539 cites W2965027642 @default.
• W3121781539 cites W2972859860 @default.
• W3121781539 cites W2973991018 @default.
• W3121781539 cites W2999282261 @default.
• W3121781539 cites W3006262357 @default.
• W3121781539 cites W4229638581 @default.
• W3121781539 doi "https://doi.org/10.1016/j.clml.2021.01.013" @default.
• W3121781539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33610500" @default.
• W3121781539 hasPublicationYear "2021" @default.
• W3121781539 type Work @default.
• W3121781539 sameAs 3121781539 @default.
• W3121781539 citedByCount "7" @default.
• W3121781539 countsByYear W31217815392021 @default.
• W3121781539 countsByYear W31217815392022 @default.
• W3121781539 countsByYear W31217815392023 @default.
• W3121781539 crossrefType "journal-article" @default.
• W3121781539 hasAuthorship W3121781539A5000200633 @default.
• W3121781539 hasAuthorship W3121781539A5003525440 @default.
• W3121781539 hasAuthorship W3121781539A5009172669 @default.
• W3121781539 hasAuthorship W3121781539A5010182646 @default.
• W3121781539 hasAuthorship W3121781539A5010790189 @default.
• W3121781539 hasAuthorship W3121781539A5016641243 @default.
• W3121781539 hasAuthorship W3121781539A5018899927 @default.
• W3121781539 hasAuthorship W3121781539A5028565626 @default.
• W3121781539 hasAuthorship W3121781539A5028970724 @default.
• W3121781539 hasAuthorship W3121781539A5030407146 @default.
• W3121781539 hasAuthorship W3121781539A5034182883 @default.
• W3121781539 hasAuthorship W3121781539A5035825967 @default.
• W3121781539 hasAuthorship W3121781539A5038473767 @default.
• W3121781539 hasAuthorship W3121781539A5040835120 @default.
• W3121781539 hasAuthorship W3121781539A5042926098 @default.
• W3121781539 hasAuthorship W3121781539A5043047671 @default.
• W3121781539 hasAuthorship W3121781539A5043068650 @default.
• W3121781539 hasAuthorship W3121781539A5058462170 @default.

• next